247 related articles for article (PubMed ID: 30469511)
1. Aberrant Epigenetic Regulation in Head and Neck Cancer Due to Distinct EZH2 Overexpression and DNA Hypermethylation.
Mochizuki D; Misawa Y; Kawasaki H; Imai A; Endo S; Mima M; Yamada S; Nakagawa T; Kanazawa T; Misawa K
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30469511
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.
Cao W; Feng Z; Cui Z; Zhang C; Sun Z; Mao L; Chen W
Cancer; 2012 Jun; 118(11):2858-71. PubMed ID: 21989926
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation.
Gannon OM; Merida de Long L; Endo-Munoz L; Hazar-Rethinam M; Saunders NA
Clin Cancer Res; 2013 Jan; 19(2):428-41. PubMed ID: 23186778
[TBL] [Abstract][Full Text] [Related]
4. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
[TBL] [Abstract][Full Text] [Related]
5. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
Chang JW; Gwak SY; Shim GA; Liu L; Lim YC; Kim JM; Jung MG; Koo BS
Oral Oncol; 2016 Jan; 52():66-74. PubMed ID: 26604082
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Sal-like protein 4 in head and neck cancer: epigenetic effects and clinical correlations.
Misawa K; Misawa Y; Mima M; Yamada S; Imai A; Mochizuki D; Nakagawa T; Kurokawa T; Endo S; Kawasaki H; Brenner JC; Mineta H
Cell Oncol (Dordr); 2020 Aug; 43(4):631-641. PubMed ID: 32240499
[TBL] [Abstract][Full Text] [Related]
7. X-linked FHL1 as a novel therapeutic target for head and neck squamous cell carcinoma.
Cao W; Liu J; Xia R; Lin L; Wang X; Xiao M; Zhang C; Li J; Ji T; Chen W
Oncotarget; 2016 Mar; 7(12):14537-50. PubMed ID: 26908444
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas.
Lindsay CD; Kostiuk MA; Harris J; O'Connell DA; Seikaly H; Biron VL
Clin Epigenetics; 2017; 9():95. PubMed ID: 28878842
[TBL] [Abstract][Full Text] [Related]
9. Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC.
Zhou X; Ren Y; Kong L; Cai G; Sun S; Song W; Wang Y; Jin R; Qi L; Mei M; Wang X; Kang C; Li M; Zhang L
Oncotarget; 2015 Oct; 6(32):33720-32. PubMed ID: 26378043
[TBL] [Abstract][Full Text] [Related]
10.
Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; Franzen A; Dietrich J; Kristiansen G; Bootz F; Schröck A; Dietrich D
Clin Epigenetics; 2017; 9():12. PubMed ID: 28174607
[TBL] [Abstract][Full Text] [Related]
11. EZH2 overexpression in head and neck cancer is related to lymph node metastasis.
Nienstedt JC; Schroeder C; Clauditz T; Simon R; Sauter G; Muenscher A; Blessmann M; Hanken H; Pflug C
J Oral Pathol Med; 2018 Mar; 47(3):240-245. PubMed ID: 29285811
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.
Misawa K; Mochizuki D; Imai A; Endo S; Mima M; Misawa Y; Kanazawa T; Carey TE; Mineta H
Oncotarget; 2016 May; 7(18):26087-98. PubMed ID: 27027429
[TBL] [Abstract][Full Text] [Related]
14. Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients.
Liu F; Gu L; Cao Y; Fan X; Zhang F; Sang M
Biomarkers; 2016; 21(1):80-90. PubMed ID: 26631178
[TBL] [Abstract][Full Text] [Related]
15. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma.
Bennett KL; Hackanson B; Smith LT; Morrison CD; Lang JC; Schuller DE; Weber F; Eng C; Plass C
Cancer Res; 2007 May; 67(10):4657-64. PubMed ID: 17510391
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.
Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H
Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450
[TBL] [Abstract][Full Text] [Related]
18. Polycomb repressive complex 2 and its core component EZH2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma.
Cheng Y; Song Z; Fang X; Tang Z
Clin Epigenetics; 2024 Apr; 16(1):54. PubMed ID: 38600608
[TBL] [Abstract][Full Text] [Related]
19. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of the Roles and Prognostic Value of RNA-Binding Proteins in Head and Neck Squamous Cell Carcinoma.
Jin Y; Qin X
DNA Cell Biol; 2020 Oct; 39(10):1789-1798. PubMed ID: 32716650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
